SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Therapies, estimates DelveInsight

The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others.

DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

For a detailed understanding of the SSc-ILD market outlook, therapy adoption, treatment landscape, and epidemiological patterns, explore the Systemic Sclerosis-associated Interstitial Lung Disease Market Forecast - https://www.delveinsight.com/sample-request/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report:
• The SSc-ILD market was valued at approximately USD 750 million in 2022 and is projected to expand at a robust CAGR throughout the forecast period from 2020 to 2034.
• In November 2024, aTyr Pharma, Inc. announced ongoing patient enrollment for its Phase II EFZO-CONNECTTM clinical trial, designed to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with systemic sclerosis-associated interstitial lung disease. This randomized, double-blind, placebo-controlled study spans 28 weeks and consists of three parallel cohorts. Patients are assigned in a 2:2:1 ratio to receive either 270 mg or 450 mg of efzofitimod, or placebo, administered intravenously once a month for six doses. The study aims to enroll up to 25 SSc-ILD patients and is actively recruiting across multiple clinical sites in the United States.
• The current SSc-ILD pipeline features several promising investigational therapies expected to influence future market dynamics. Notable candidates include PRA023, Belimumab (GSK1550188), Vixarelimab (KPL-716), along with other emerging agents.
• In 2022, the total diagnosed prevalent population of Systemic Sclerosis-associated Interstitial Lung Disease across the seven major markets (7MM) was estimated at approximately 53,178 cases. This figure is anticipated to rise significantly, driven by a strong CAGR during the 2020-2034 study period.
• Among European countries, the United Kingdom reported the highest number of diagnosed SSc-ILD cases in 2022, with nearly 4,269 patients. Italy and France followed closely, whereas Germany recorded the lowest diagnosed prevalence during the same year.
• DelveInsight's analysis indicates that in 2023, SSc-ILD diagnoses were most common among individuals aged 65 years and above, while the pediatric population aged 0-18 years accounted for the fewest cases.
• Leading Systemic Sclerosis-associated Interstitial Lung Disease Companies: Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others.
• Gender-based epidemiological analysis reveals that females have a higher likelihood of developing SSc-ILD compared to males.
• The SSc-ILD market is expected to witness substantial growth during the forecast period, driven by increasing disease prevalence and improved awareness. Additionally, the introduction of multiple pipeline therapies across different development stages is poised to significantly reshape market dynamics.

SSc-ILD Overview
Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) is a serious complication arising from systemic sclerosis, also referred to as scleroderma. Systemic sclerosis is a chronic autoimmune connective tissue disorder marked by immune dysregulation, vascular abnormalities, and excessive collagen accumulation affecting the skin and internal organs.

Request a free sample copy of the Systemic Sclerosis-associated Interstitial Lung Disease Market Forecast, Size, and Share Analysis Report - https://www.delveinsight.com/sample-request/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

SSc-ILD Epidemiology
The epidemiology section examines historical, current, and projected trends in SSc-ILD across the seven major markets from 2020 to 2034. It identifies key drivers behind observed and anticipated trends by integrating data from multiple studies and expert opinions. This section also offers an in-depth evaluation of the diagnosed patient population and future epidemiological shifts.
Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Segmentation Covered in the Report:
The SSc-ILD market report provides epidemiological insights for the 2020-2034 period across the 7MM, segmented into:
• Overall prevalence of SSc-ILD
• Severity-based prevalence of SSc-ILD
• Gender-specific prevalence of SSc-ILD
• Diagnosed cases of episodic and chronic SSc-ILD

Download the report to gain insights into the key factors shaping SSc-ILD epidemiological trends - https://www.delveinsight.com/sample-request/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Systemic Sclerosis-associated Interstitial Lung Disease Drug Uptake and Pipeline Progress
The drug uptake analysis evaluates the adoption rates of recently launched therapies as well as those expected to enter the SSc-ILD market during the forecast period. It includes assessments of drug-wise market penetration, patient uptake across therapies, and revenue performance of individual products.
The therapeutics assessment further identifies drugs demonstrating the fastest adoption and explains the factors contributing to their widespread use. It also compares available and emerging therapies based on market share.
Additionally, the report provides a detailed overview of SSc-ILD pipeline development activities, highlighting therapeutic candidates at various stages of clinical development and the companies driving innovation. Recent strategic developments such as partnerships, mergers and acquisitions, licensing agreements, patent activity, and other advancements-are also analyzed.

Systemic Sclerosis-associated Interstitial Lung Disease Therapies and Associated Companies
• ACTEMRA/ROACTEMRA (tocilizumab): Roche
• PRA023: Prometheus Biosciences, Inc./Merck
• Belimumab: GlaxoSmithKline
• Vixarelimab: Genentech, Inc.
• MK-2225 (ACE-1334): Acceleron/Merck
• Nintedanib: Boehringer Ingelheim
• Bosentan: Actelion
• Cyclophosphamide: Hôpital Claude-Huriez
• GenSci048: Changchun GeneScience Pharmaceutical

Explore in-depth insights on therapies poised to capture significant SSc-ILD market share - https://www.delveinsight.com/sample-request/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Systemic Sclerosis-associated Interstitial Lung Disease Market Strengths
The limited availability of therapeutic options within both the current market and emerging pipeline presents a favorable opportunity for new therapies to capture substantial market share with relatively lower competitive pressure.
Systemic Sclerosis-associated Interstitial Lung Disease Market Opportunities
The lack of approved and effective treatment options creates significant scope for investment and innovation in the development of novel SSc-ILD therapies.

Scope of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report
• Study Period: 2020-2034
• Geographic Coverage: 7MM (United States, EU5-Germany, France, Italy, Spain, United Kingdom-and Japan)
• Key Companies: Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others
• Key Therapies: ACTEMRA/ROACTEMRA, PRA023, Belimumab, Vixarelimab, MK-2225, Nintedanib, Bosentan, Cyclophosphamide, GenSci048, among others
• Therapeutic Assessment: Marketed and emerging SSc-ILD therapies
• Market Dynamics: Key drivers and barriers
• Competitive Intelligence: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, and market entry strategies
• Additional Insights: Unmet needs, KOL perspectives, analyst opinions, market access, and reimbursement landscape

For deeper insights into companies developing SSc-ILD treatments, explore the SSc-ILD Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction to the SSc-ILD Market Report
2. Executive Summary
3. Systemic Sclerosis-associated Interstitial Lung Disease SWOT Analysis
4. Systemic Sclerosis-associated Interstitial Lung Disease Patient Share Overview
5. Systemic Sclerosis-associated Interstitial Lung Disease Market Snapshot
6. Disease Background and Overview
7. Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology and Patient Population
8. Country-Specific Patient Analysis
9. Current Systemic Sclerosis-associated Interstitial Lung Disease Treatment Practices
10. Systemic Sclerosis-associated Interstitial Lung Disease Unmet Medical Need
11. Systemic Sclerosis-associated Interstitial Lung Disease Emerging Therapies
12. Systemic Sclerosis-associated Interstitial Lung Disease Market Outlook
13. Country-Wise Market Analysis (2020-2034)
14. Systemic Sclerosis-associated Interstitial Lung Disease Market Access and Reimbursement
15. Systemic Sclerosis-associated Interstitial Lung Disease Market Drivers
16. Systemic Sclerosis-associated Interstitial Lung Disease Market Barriers
17. Appendix
18. Research Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.